The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions

Type 1 Diabetes MellitusHypoglycemia Unawareness

Interventions

DEVICE

Real-time continuous glucose monitor

Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)

Trial Locations (1)

VU University Medical Center, Amsterdam

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Amsterdam UMC, location VUmc

OTHER

NCT01787903 - The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA | Biotech Hunter | Biotech Hunter